Loading...

INBX INHIBRX BIOSCIENCES INC Expansion Plans 8-K Filing

NHBR

NBX

INHIBRX BIOSCIENCES INC

(INBX)

2026 8-K

Financial Results Announced

Clinical Trial Update

Clinical Data Update

Financial Results Announcement

Corporate Presentation Update

Clinical Trial Update

Financial Results Announced

Positive Trial Results

Financial Results Announcement

Financial Statements

Management Changes

Financial Results

Ozekibart Data Release

Financial Results

External Links:

On May 11, 2026, Inhibrx Biosciences announced positive interim results for its clinical trial of INBRX-106, showing a 44% response rate in patients versus 21% for the control group, indicating a significant potential increase in treatment efficacy for head and neck cancer.

AI Assistant

INHIBRX BIOSCIENCES INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.